TapewireFind a company

person · Reporting owner

KASINGER JAMES R.

Disclosed activity across 1 company

Tapewire entity
42394
SEC CIK
0001708172

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
CRISPR Therapeutics AGCRSP · Entity 3852General Counsel and SecretaryOctober 06, 2026October 08, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CRISPR Therapeutics AG

Report date October 06, 2026 · Filed October 08, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common SharesSEC Table I · non-derivativeDirect94,784 Ending reported balance After 2026-10-06 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-10-06 · Exercise / conversion · Acquired 1,990 · Balance 96,774

Row 2 · 2026-10-06 · Sale · Disposed 1,990 · Balance 94,784

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2026.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.62 · Expires 2027-05-31Direct81,242 Reported balance After 2026-10-06 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-10-06 · Exercise / conversion · Disposed 1,990 · Balance 81,242

F3: This option was granted on May 31, 2017 with respect to 123,000 Common Shares of which 25% shall vest on May 31, 2018 and the remaining 75% shall vest monthly thereafter for 36 months.

Filing footnotes · ownership attribution and instrument terms

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2026.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3: This option was granted on May 31, 2017 with respect to 123,000 Common Shares of which 25% shall vest on May 31, 2018 and the remaining 75% shall vest monthly thereafter for 36 months.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
October 06, 2026 Filed Oct 8, 2026 21:35 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionStock Option (Right to Buy) · Derivative 1,990 $0.00 Strike: $13.62 $0.00
Disclosure

SEC source: 0001193125-26-418101 · ownership.xml · derivative · entry 3

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 81,242

Underlying: Common Shares · 1,990 shares

Expires 2027-05-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option was granted on May 31, 2017 with respect to 123,000 Common Shares of which 25% shall vest on May 31, 2018 and the remaining 75% shall vest monthly thereafter for 36 months.

Read SEC document
October 06, 2026 Filed Oct 8, 2026 21:35 UTC CRISPR Therapeutics AG CRSP · Entity 3852 SaleCommon Shares 1,990 $60.04 $119,481.19
Disclosure

SEC source: 0001193125-26-418101 · ownership.xml · nonDerivative · entry 2

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 94,784

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2026.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
October 06, 2026 Filed Oct 8, 2026 21:35 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionCommon Shares 1,990 $13.62 $27,103.80
Disclosure

SEC source: 0001193125-26-418101 · ownership.xml · nonDerivative · entry 1

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 96,774

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
September 22, 2026 Filed Sep 24, 2026 21:35 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionStock Option (Right to Buy) · Derivative 10,400 $0.00 Strike: $13.62 $0.00
Disclosure

SEC source: 0001193125-26-401237 · ownership.xml · derivative · entry 3

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 83,232

Underlying: Common Shares · 10,400 shares

Expires 2027-05-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: This option was granted on May 31, 2017 with respect to 123,000 Common Shares of which 25% shall vest on May 31, 2018 and the remaining 75% shall vest monthly thereafter for 36 months.

Read SEC document
September 22, 2026 Filed Sep 24, 2026 21:35 UTC CRISPR Therapeutics AG CRSP · Entity 3852 SaleCommon Shares 10,400 $60.24 $626,459.60
Disclosure

SEC source: 0001193125-26-401237 · ownership.xml · nonDerivative · entry 2

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 94,784

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2026.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
September 22, 2026 Filed Sep 24, 2026 21:35 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionCommon Shares 10,400 $13.62 $141,648.00
Disclosure

SEC source: 0001193125-26-401237 · ownership.xml · nonDerivative · entry 1

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 105,184

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 476 shares acquired under the CRISPR Therapeutics AG 2026 Employee Stock Purchase Plan.

Read SEC document
May 29, 2026 Filed Jun 2, 2026 21:42 UTC CRISPR Therapeutics AG CRSP · Entity 3852 GrantRestricted Stock Units · Derivative 17,000 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-253929 · ownership.xml · derivative · entry 1

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,000

Underlying: Common Shares · 17,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F2 · derivative.exercise_date: This restricted stock unit award was granted on May 29, 2026 with respect to 17,000 Common Shares, with 100% of the shares vesting on November 29, 2028.

F2 · derivative.expiration_date: This restricted stock unit award was granted on May 29, 2026 with respect to 17,000 Common Shares, with 100% of the shares vesting on November 29, 2028.

Read SEC document
March 23, 2026 Filed Mar 24, 2026 21:38 UTC CRISPR Therapeutics AG CRSP · Entity 3852 SaleCommon Shares 3,182 $46.78 $148,853.96
Disclosure

SEC source: 0001193125-26-122274 · ownership.xml · nonDerivative · entry 2

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 94,308

F3 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

Read SEC document
March 20, 2026 Filed Mar 24, 2026 21:38 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionRestricted Stock Units · Derivative 6,250 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-122274 · ownership.xml · derivative · entry 5

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Shares · 6,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F1 · kind: These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031.

F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F6 · derivative.exercise_date: This restricted stock unit award was granted on March 20, 2024 with respect to 25,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028.

F6 · derivative.expiration_date: This restricted stock unit award was granted on March 20, 2024 with respect to 25,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028.

Read SEC document
March 20, 2026 Filed Mar 24, 2026 21:38 UTC CRISPR Therapeutics AG CRSP · Entity 3852 GrantRestricted Stock Units · Derivative 25,000 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-122274 · ownership.xml · derivative · entry 4

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Shares · 25,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F1 · kind: These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031.

F5 · derivative.exercise_date: This restricted stock unit award was granted on March 20, 2026 with respect to 25,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2027 , (ii) one quarter of the shares vesting on March 20, 2028, (iii) one quarter of the shares vesting on March 20, 2029, and (iv) one quarter of the shares vesting on March 20, 2030.

F5 · derivative.expiration_date: This restricted stock unit award was granted on March 20, 2026 with respect to 25,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2027 , (ii) one quarter of the shares vesting on March 20, 2028, (iii) one quarter of the shares vesting on March 20, 2029, and (iv) one quarter of the shares vesting on March 20, 2030.

Read SEC document
March 20, 2026 Filed Mar 24, 2026 21:38 UTC CRISPR Therapeutics AG CRSP · Entity 3852 GrantStock Option (Right to Buy) · Derivative 38,499 $0.00 Strike: $46.24 $0.00
Disclosure

SEC source: 0001193125-26-122274 · ownership.xml · derivative · entry 3

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,499

Underlying: Common Shares · 38,499 shares

Expires 2036-03-20

F1 · kind: These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031.

F4 · derivative.exercise_date: This option was granted on March 20, 2026 with respect to 38,499 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 20, 2026.

Read SEC document
March 20, 2026 Filed Mar 24, 2026 21:38 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionCommon Shares 6,250 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-122274 · ownership.xml · nonDerivative · entry 1

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 97,490

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031.

F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

Read SEC document
March 16, 2026 Filed Mar 17, 2026 21:35 UTC CRISPR Therapeutics AG CRSP · Entity 3852 SaleCommon Shares 3,450 $48.26 $166,497.00
Disclosure

SEC source: 0001193125-26-111281 · ownership.xml · nonDerivative · entry 2

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 91,240

F3 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

Read SEC document
March 14, 2026 Filed Mar 17, 2026 21:35 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionRestricted Stock Units · Derivative 6,875 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-111281 · ownership.xml · derivative · entry 3

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,625

Underlying: Common Shares · 6,875 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F1 · kind: These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031.

F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F4 · derivative.exercise_date: This restricted stock unit award was granted on March 14, 2025 with respect to 27,500 Common Shares, with (i) one quarter of the shares vesting on March 14, 2026, (ii) one quarter of the shares vesting on March 14, 2027, (iii) one quarter of the shares vesting on March 14, 2028, and (iv) one quarter of the shares vesting on March 14, 2029.

F4 · derivative.expiration_date: This restricted stock unit award was granted on March 14, 2025 with respect to 27,500 Common Shares, with (i) one quarter of the shares vesting on March 14, 2026, (ii) one quarter of the shares vesting on March 14, 2027, (iii) one quarter of the shares vesting on March 14, 2028, and (iv) one quarter of the shares vesting on March 14, 2029.

Read SEC document
March 14, 2026 Filed Mar 17, 2026 21:35 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionCommon Shares 6,875 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-111281 · ownership.xml · nonDerivative · entry 1

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 94,690

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031.

F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

Read SEC document
March 11, 2026 Filed Mar 12, 2026 21:35 UTC CRISPR Therapeutics AG CRSP · Entity 3852 SaleCommon Shares 2,800 $52.80 $147,840.00
Disclosure

SEC source: 0001193125-26-104481 · ownership.xml · nonDerivative · entry 2

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,815

F3 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

Read SEC document
March 10, 2026 Filed Mar 12, 2026 21:35 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionRestricted Stock Units · Derivative 5,500 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-104481 · ownership.xml · derivative · entry 3

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,500

Underlying: Common Shares · 5,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F1 · kind: These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031.

F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F4 · derivative.exercise_date: This restricted stock unit award was granted on March 10, 2023 with respect to 22,000 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027.

F4 · derivative.expiration_date: This restricted stock unit award was granted on March 10, 2023 with respect to 22,000 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027.

Read SEC document
March 10, 2026 Filed Mar 12, 2026 21:35 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionCommon Shares 5,500 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-104481 · ownership.xml · nonDerivative · entry 1

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,615

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031.

F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

Read SEC document
February 19, 2026 Filed Feb 20, 2026 22:35 UTC CRISPR Therapeutics AG CRSP · Entity 3852 SaleCommon Shares 2,112 $52.58 $111,048.96
Disclosure

SEC source: 0001193125-26-061710 · ownership.xml · nonDerivative · entry 2

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,115

F2 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

Read SEC document
February 18, 2026 Filed Feb 20, 2026 22:35 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionRestricted Stock Units · Derivative 3,825 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-061710 · ownership.xml · derivative · entry 3

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 3,825 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F3 · derivative.exercise_date: This restricted stock unit award was granted on February 18, 2022 with respect to 15,300 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026.

F3 · derivative.expiration_date: This restricted stock unit award was granted on February 18, 2022 with respect to 15,300 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026.

Read SEC document
February 18, 2026 Filed Feb 20, 2026 22:35 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionCommon Shares 3,825 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-061710 · ownership.xml · nonDerivative · entry 1

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,227

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

Read SEC document
October 14, 2025 Filed Oct 15, 2025 21:35 UTC CRISPR Therapeutics AG CRSP · Entity 3852 SaleCommon Shares 1,076 $66.60 $71,661.60
Disclosure

SEC source: 0001193125-25-240437 · ownership.xml · nonDerivative · entry 2

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,402

F3 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

Read SEC document
October 13, 2025 Filed Oct 15, 2025 21:35 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionRestricted Stock Units · Derivative 2,114 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-25-240437 · ownership.xml · derivative · entry 3

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,113

Underlying: Common Shares · 2,114 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F4 · derivative.exercise_date: This restricted stock unit award was granted on October 13, 2023 with respect to 6,340 Common Shares, with (i) one third of the shares vesting on October 13, 2024, (ii) one third of the shares vesting on October 13, 2025, and (iii) one third of the shares vesting on October 13, 2026.

F4 · derivative.expiration_date: This restricted stock unit award was granted on October 13, 2023 with respect to 6,340 Common Shares, with (i) one third of the shares vesting on October 13, 2024, (ii) one third of the shares vesting on October 13, 2025, and (iii) one third of the shares vesting on October 13, 2026.

Read SEC document
October 13, 2025 Filed Oct 15, 2025 21:35 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionCommon Shares 2,114 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-25-240437 · ownership.xml · nonDerivative · entry 1

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,478

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F2 · balance_after: Includes 635 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan.

Read SEC document
October 03, 2025 Filed Oct 3, 2025 21:36 UTC CRISPR Therapeutics AG CRSP · Entity 3852 GrantStock Option (Right to Buy) · Derivative 16,500 $0.00 Strike: $67.74 $0.00
Disclosure

SEC source: 0001193125-25-230506 · ownership.xml · derivative · entry 1

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,500

Underlying: Common Shares · 16,500 shares

Expires 2035-10-03

F1 · derivative.exercise_date: This option was granted on October 3, 2025 with respect to 16,500 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 3, 2025.

Read SEC document
March 21, 2025 Filed Mar 24, 2025 21:35 UTC CRISPR Therapeutics AG CRSP · Entity 3852 SaleCommon Shares 3,185 $41.23 $131,317.55
Disclosure

SEC source: 0000950170-25-043972 · ownership.xml · nonDerivative · entry 2

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,729

F2 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

Read SEC document
March 20, 2025 Filed Mar 24, 2025 21:35 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionRestricted Stock Units · Derivative 6,250 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-043972 · ownership.xml · derivative · entry 3

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,750

Underlying: Common Shares · 6,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F3 · derivative.exercise_date: This restricted stock unit award was granted on March 20, 2024 with respect to 25,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028.

F3 · derivative.expiration_date: This restricted stock unit award was granted on March 20, 2024 with respect to 25,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028.

Read SEC document
March 20, 2025 Filed Mar 24, 2025 21:35 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionCommon Shares 6,250 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-043972 · ownership.xml · nonDerivative · entry 1

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,914

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

Read SEC document
March 14, 2025 Filed Mar 18, 2025 21:35 UTC CRISPR Therapeutics AG CRSP · Entity 3852 GrantRestricted Stock Units · Derivative 27,500 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-041467 · ownership.xml · derivative · entry 2

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,500

Underlying: Common Shares · 27,500 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F3 · derivative.exercise_date: This restricted stock unit award was granted on March 14, 2025 with respect to 27,500 Common Shares, with (i) one quarter of the shares vesting on March 14, 2026, (ii) one quarter of the shares vesting on March 14, 2027, (iii) one quarter of the shares vesting on March 14, 2028, and (iv) one quarter of the shares vesting on March 14, 2029.

F3 · derivative.expiration_date: This restricted stock unit award was granted on March 14, 2025 with respect to 27,500 Common Shares, with (i) one quarter of the shares vesting on March 14, 2026, (ii) one quarter of the shares vesting on March 14, 2027, (iii) one quarter of the shares vesting on March 14, 2028, and (iv) one quarter of the shares vesting on March 14, 2029.

Read SEC document
March 14, 2025 Filed Mar 18, 2025 21:35 UTC CRISPR Therapeutics AG CRSP · Entity 3852 GrantStock Option (Right to Buy) · Derivative 36,666 $0.00 Strike: $42.12 $0.00
Disclosure

SEC source: 0000950170-25-041467 · ownership.xml · derivative · entry 1

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,666

Underlying: Common Shares · 36,666 shares

Expires 2035-03-14

F1 · derivative.exercise_date: This option was granted on March 14, 2025 with respect to 36,666 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 14, 2025.

Read SEC document
March 12, 2025 Filed Mar 12, 2025 23:05 UTC CRISPR Therapeutics AG CRSP · Entity 3852 SaleCommon Shares 1,116 $43.32 $48,345.12
Disclosure

SEC source: 0000950170-25-038215 · ownership.xml · nonDerivative · entry 4

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,664

F2 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

Read SEC document
March 11, 2025 Filed Mar 12, 2025 23:05 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionRestricted Stock Units · Derivative 2,250 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-038215 · ownership.xml · derivative · entry 6

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 2,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F4 · derivative.exercise_date: This restricted stock unit award was granted on March 11, 2021 with respect to 9,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025.

F4 · derivative.expiration_date: This restricted stock unit award was granted on March 11, 2021 with respect to 9,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025.

Read SEC document
March 11, 2025 Filed Mar 12, 2025 23:05 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionCommon Shares 2,250 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-038215 · ownership.xml · nonDerivative · entry 3

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,780

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

Read SEC document
March 11, 2025 Filed Mar 12, 2025 23:05 UTC CRISPR Therapeutics AG CRSP · Entity 3852 SaleCommon Shares 2,850 $42.42 $120,897.00
Disclosure

SEC source: 0000950170-25-038215 · ownership.xml · nonDerivative · entry 2

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,530

F2 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

Read SEC document
March 10, 2025 Filed Mar 12, 2025 23:05 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionRestricted Stock Units · Derivative 5,500 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-038215 · ownership.xml · derivative · entry 5

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,000

Underlying: Common Shares · 5,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F3 · derivative.exercise_date: This restricted stock unit award was granted on March 10, 2023 with respect to 22,000 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027.

F3 · derivative.expiration_date: This restricted stock unit award was granted on March 10, 2023 with respect to 22,000 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027.

Read SEC document
March 10, 2025 Filed Mar 12, 2025 23:05 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionCommon Shares 5,500 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-038215 · ownership.xml · nonDerivative · entry 1

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,380

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

Read SEC document
February 19, 2025 Filed Feb 19, 2025 22:35 UTC CRISPR Therapeutics AG CRSP · Entity 3852 SaleCommon Shares 1,947 $52.80 $102,801.60
Disclosure

SEC source: 0000950170-25-023386 · ownership.xml · nonDerivative · entry 4

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,880

F2 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

Read SEC document
February 18, 2025 Filed Feb 19, 2025 22:35 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionRestricted Stock Units · Derivative 3,825 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-023386 · ownership.xml · derivative · entry 6

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,825

Underlying: Common Shares · 3,825 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F4 · derivative.exercise_date: This restricted stock unit award was granted on February 18, 2022 with respect to 15,300 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026.

F4 · derivative.expiration_date: This restricted stock unit award was granted on February 18, 2022 with respect to 15,300 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026.

Read SEC document
February 18, 2025 Filed Feb 19, 2025 22:35 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionCommon Shares 3,825 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-023386 · ownership.xml · nonDerivative · entry 3

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,827

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

Read SEC document
February 18, 2025 Filed Feb 19, 2025 22:35 UTC CRISPR Therapeutics AG CRSP · Entity 3852 SaleCommon Shares 9,595 $53.85 $516,690.75
Disclosure

SEC source: 0000950170-25-023386 · ownership.xml · nonDerivative · entry 2

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,002

F2 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

Read SEC document
February 16, 2025 Filed Feb 19, 2025 22:35 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionRestricted Stock Units · Derivative 20,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-023386 · ownership.xml · derivative · entry 5

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 20,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F3 · derivative.exercise_date: This restricted stock unit award was granted on August 16, 2022 with respect to 20,000 Common Shares, with 100% of the shares vesting on February 16, 2025.

F3 · derivative.expiration_date: This restricted stock unit award was granted on August 16, 2022 with respect to 20,000 Common Shares, with 100% of the shares vesting on February 16, 2025.

Read SEC document
February 16, 2025 Filed Feb 19, 2025 22:35 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionCommon Shares 20,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-023386 · ownership.xml · nonDerivative · entry 1

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,597

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

Read SEC document
October 16, 2024 Filed Oct 18, 2024 21:35 UTC CRISPR Therapeutics AG CRSP · Entity 3852 GrantRestricted Stock Units · Derivative 30,000 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-115696 · ownership.xml · derivative · entry 2

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Shares · 30,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F3 · derivative.exercise_date: This restricted stock unit award was granted on October 16, 2024 with respect to 30,000 Common Shares, with 100% of the shares vesting on October 16, 2027.

F3 · derivative.expiration_date: This restricted stock unit award was granted on October 16, 2024 with respect to 30,000 Common Shares, with 100% of the shares vesting on October 16, 2027.

Read SEC document
October 16, 2024 Filed Oct 18, 2024 21:35 UTC CRISPR Therapeutics AG CRSP · Entity 3852 GrantStock Option (Right to Buy) · Derivative 18,333 $0.00 Strike: $49.00 $0.00
Disclosure

SEC source: 0000950170-24-115696 · ownership.xml · derivative · entry 1

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,333

Underlying: Common Shares · 18,333 shares

Expires 2034-10-16

F1 · derivative.exercise_date: This option was granted on October 16, 2024 with respect to 18,333 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 16, 2024.

Read SEC document
October 14, 2024 Filed Oct 15, 2024 22:00 UTC CRISPR Therapeutics AG CRSP · Entity 3852 SaleCommon Shares 1,089 $46.28 $50,398.92
Disclosure

SEC source: 0000950170-24-114787 · ownership.xml · nonDerivative · entry 2

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,597

F3 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

Read SEC document
October 13, 2024 Filed Oct 15, 2024 22:00 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionRestricted Stock Units · Derivative 2,113 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-114787 · ownership.xml · derivative · entry 3

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,227

Underlying: Common Shares · 2,113 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F4 · derivative.exercise_date: This restricted stock unit award was granted on October 13, 2023 with respect to 6,340 Common Shares, with (i) one third of the shares vesting on October 13, 2024, (ii) one third of the shares vesting on October 13, 2025, and (iii) one third of the shares vesting on October 13, 2026.

F4 · derivative.expiration_date: This restricted stock unit award was granted on October 13, 2023 with respect to 6,340 Common Shares, with (i) one third of the shares vesting on October 13, 2024, (ii) one third of the shares vesting on October 13, 2025, and (iii) one third of the shares vesting on October 13, 2026.

Read SEC document
October 13, 2024 Filed Oct 15, 2024 22:00 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionCommon Shares 2,113 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-114787 · ownership.xml · nonDerivative · entry 1

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,686

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F2 · balance_after: Includes 399 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan.

Read SEC document
March 20, 2024 Filed Mar 22, 2024 21:45 UTC CRISPR Therapeutics AG CRSP · Entity 3852 GrantRestricted Stock Units · Derivative 25,000 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-035517 · ownership.xml · derivative · entry 2

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Shares · 25,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F3 · derivative.exercise_date: This restricted stock unit award was granted on March 20, 2024 with respect to 25,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028.

F3 · derivative.expiration_date: This restricted stock unit award was granted on March 20, 2024 with respect to 25,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028.

Read SEC document
March 20, 2024 Filed Mar 22, 2024 21:45 UTC CRISPR Therapeutics AG CRSP · Entity 3852 GrantStock Option (Right to Buy) · Derivative 33,333 $0.00 Strike: $72.94 $0.00
Disclosure

SEC source: 0000950170-24-035517 · ownership.xml · derivative · entry 1

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,333

Underlying: Common Shares · 33,333 shares

Expires 2034-03-20

F1 · derivative.exercise_date: This option was granted on March 20, 2024 with respect to 33,333 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 20, 2024.

Read SEC document
March 12, 2024 Filed Mar 12, 2024 21:45 UTC CRISPR Therapeutics AG CRSP · Entity 3852 SaleCommon Shares 1,146 $74.44 $85,308.24
Disclosure

SEC source: 0000950170-24-030190 · ownership.xml · nonDerivative · entry 4

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,174

F2 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.